Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJingbo YuNENicole Engel-NitzJGJohn J. Galvin

Discussion

Loading...

Member takes

Overview

Observational analysis shows ruxolitinib reduced corticosteroid dosage in chronic graft-versus-host disease, suggesting improved treatment approaches.

Key Points

  • Ruxolitinib therapy achieved corticosteroid discontinuation or reduction in 90% of patients within one year.
  • Patients had a median treatment length of 242 days overall, indicating significant long-term use of ruxolitinib.
  • This retrospective analysis employed administrative claims data from multiple health plan members to assess ruxolitinib's impact.
  • Findings suggest that ruxolitinib serves as a viable long-term treatment option for chronic graft-versus-host disease.

Cite This Study

Yu et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1f6https://doi.org/10.1182/blood-2025-2452
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database2025
  2. 2Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database2025
  3. 3Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study2025 · 1 citations
  4. 4An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation2025
  5. 5Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis2025 · 5 citations